share_log

Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target

Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target

杰富瑞将BioCryst Pharma升级为收购,宣布目标股价为11美元
Benzinga ·  2023/08/04 08:41

Jefferies analyst Maury Raycroft upgrades BioCryst Pharma (NASDAQ:BCRX) from Hold to Buy and announces $11 price target.

杰富瑞分析师莫里·雷克罗夫特将BioCryst Pharma(纳斯达克股票代码:BCRX)从持有上调至买入,并宣布了11美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发